Study guide
8.3 Kidd System
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
8.3 Kidd System
Key Takeaways Explain This Topic AI
Jka and Jkb sit on the SLC14A1 urea transporter; Jk3 is the high-prevalence antigen missing only on Jk(a−b−) cells.
Jk(a−b−) is rare and enriched in Polynesian ancestry; those cells resist lysis in 2 M urea.
Anti-Jka is infamous for delayed hemolytic transfusion reactions because the titer falls below detectability, then an anamnestic response hemolyzes the unit.
Anti-Jka and anti-Jkb are always clinically significant, show dosage, and are enhanced by enzymes; DTT does not destroy them.
Honor a historical anti-Jka even when today’s antibody screen is negative — issue Jk(a−) red cells.
Last updated: August 2026
8.3 Kidd System
Quick Answer: Jka and Jkb are antithetical antigens on the SLC14A1 urea transporter ; Jk3 is present whenever any Kidd protein is on the cell. Jk(a−b−) is rare and enriched in Polynesian ancestry ; those cells resist 2 M urea lysis . Anti-Jka is infamous for delayed hemolytic transfusion reactions : the titer falls below detectability , an anamnestic response follows transfusion of a Jk(a+) unit, and dosage plus enzyme enhancement explain why the screen looked clean. Kidd antibodies are always clinically significant . Store them as evanescent antibody history and honor historical anti-Jka even when today’s screen is negative.
Kidd is II.B.8 on the June 9, 2026 outline because it is the system that makes a technically correct current screen still the wrong crossmatch. If you remember only one honor-the-history rule on BB, this is it.
Jka, Jkb, Jk3, and the urea transporter
The Kidd glycoprotein is a urea transporter . That biochemistry is not trivia. Jk(a−b−) red cells cannot transport urea efficiently, so they resist lysis in 2 M urea — a classic screening test for the null phenotype. Ordinary Jk(a+) or Jk(b+) cells swell and lyse in urea; null cells do not. The same transporter story explains why some Jk-null people have a mild urine-concentrating defect , which the exam may mention as a clue, not as a reason to withhold transfusion.
Jka (JK1) and Jkb (JK2) are antithetical. Jk3 is the high-prevalence antigen on the Kidd protein; it is missing only on Jk(a−b−) cells. Approximate teaching frequencies:
- Phenotype European ancestry African ancestry Note
- Jk(a+b−) ~26% ~51% Double-dose Jka; best cell to rule in or out anti-Jka
- Jk(a+b+) ~50% ~41% Heterozygous; dosage can hide anti-Jka or anti-Jkb
- Jk(a−b+) ~24% ~8% Double-dose Jkb
- Jk(a−b−) Rare Rare Polynesian-enriched null; also seen in Finnish and other isolates
Jk(a−b−) is not the African malaria type. That is Duffy. Do not transplant Fy(a−b−) frequencies onto Kidd. The BB geography for the Kidd null is Polynesia / Pacific Islands (a common JK 02N splice mutation), with other founder populations as secondary mentions. Immunized Jk-null people can make anti-Jk3 , which reacts with all Jk(a+) or Jk(b+) cells and needs other Jk(a−b−) units from a rare-donor file.
Why anti-Jka is the delayed-HTR antibody
Anti-Jka is more common than anti-Jkb. Both are IgG , always clinically significant , and capable of acute or delayed HTR and usually mild HDFN . Several properties conspire to make anti-Jka the antibody that bites after the patient has already left the hospital:
Evanescent titers. After the primary immunization, anti-Jka often falls below the detection limit of the antibody screen within weeks to months. The next pretransfusion sample looks clean. The antibody is not gone; it is below the method’s sensitivity .
Anamnestic response. Re-exposure to a Jk(a+) unit restimulates memory B cells. Antibody rises over days , coats the transfused cells, and produces a delayed hemolytic transfusion reaction : falling hemoglobin, rising bilirubin and LDH, falling haptoglobin, and a newly positive DAT, often 5–14 days after transfusion. The eluate contains anti-Jka. The post-transfusion screen, which was negative last week, is now positive.
Dosage. Anti-Jka may react only with Jk(a+b−) cells and look negative with Jk(a+b+) screening cells. A two-cell screen that happens to carry Jka in single dose can miss it even when a little antibody is still present. Always try to rule Kidd out on a homozygous cell.
Enzyme enhancement. Ficin and papain strengthen Kidd reactions. An enzyme panel is how you drag a weak anti-Jka into view. Enzymes do not destroy Kidd. DTT does not destroy Kidd. If DTT knocks the antibody out, you are in Kell territory, not Kidd territory.
Complement. Some Kidd antibodies bind complement. You may see in-vitro hemolysis, mixed-field appearance after partial hemolysis, or a stronger reaction in a complement-active (serum, polyspecific AHG) system than in a plasma/IgG-only card.
Put those five together and you get the classic stem: delayed HTR, previously negative screen, anti-Jka in the eluate, and a historical note that someone, somewhere, had already identified anti-Jka last year.
Honor the history, not tonight’s screen
If anti-Jka was ever identified, issue Jk(a−) red cells for life , even when the current screen and panel are negative. The same rule applies to anti-Jkb and anti-Jk3. This is not optional courtesy. It is the intervention that prevents the delayed HTR you just described. Document the antibody in the blood-bank information system, on a wallet card if the SOP uses one, and in any receiving-hospital transfer packet. An evanescent antibody that is not stored is an evanescent antibody that will be rediscovered in the DAT of a delayed HTR.
Do not wait for the titer to come back before you phenotype units. Do not accept a computer-crossmatch-only issue on a patient whose file says anti-Jka just because today’s two-cell screen is clean. Do not substitute Jk(b−) units for a historical anti-Jka. The antigen you must avoid is the one the patient already answered to.
Unit selection once the antibody is known is ordinary antigen-negative practice: type units for Jka (or Jkb), crossmatch at IAT, and issue. Jk(a−) units are findable in most inventories (about one in four European-ancestry units is Jk(a−)). Jk(a−b−) units for anti-Jk3 are not — call the rare-donor program.
HDFN from Kidd antibodies is usually milder than anti-D or anti-K. Kidd antigens are well developed on cord cells, so the antibody can cause a positive DAT and some hemolysis, but the erythroid-suppression disaster is a Kell story, not a Kidd story. Do not manage anti-Jka pregnancies with the anti-K playbook, and do not dismiss anti-Jka in a transfusion candidate because HDFN is mild.
Exam traps
Issuing screen-compatible, Jk(a+) units to a patient with historical anti-Jka . That is the whole point of this system.
Ruling out anti-Jka on a Jk(a+b+) cell. Demand a double-dose cell.
Using DTT to confirm Kidd. DTT destroys Kell , not Kidd. Enzymes enhance Kidd.
Calling Jk(a−b−) the common African phenotype. The common African null-looking type is Fy(a−b−) .
Treating a delayed HTR workup as a new warm auto just because last week’s screen was negative. Elute the DAT-positive cells; anti-Jka is waiting there.
Withholding antigen-negative blood until you can titer the historical antibody back into view. The screen is allowed to be negative. The history is not optional.